Cannabidiol as an Adjunctive Treatment for Bipolar Depression
Status:
Terminated
Trial end date:
2020-03-24
Target enrollment:
Participant gender:
Summary
Depressive symptoms are associated with significant psychosocial impairment. However, current
treatments of bipolar depression are only partially effective.
Cannabidiol is a natural component of cannabis without psychotomimetic or addictive
properties. Cannabidiol has been shown to produce therapeutic effects including
anticonvulsive, anxiolytic, antipsychotic and neuroprotective effects. The investigators
hypothesize that treatment with cannabidiol will result in improvement of depressive and
anxiety symptoms, as well as, improvement in functioning and inflammatory biomarkers. During
the clinical trial, subjects will receive study medication (cannabidiol 150-300mg/day) or
placebo for a period of 12 weeks.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Hospital de Clinicas de Porto Alegre
Collaborators:
Federal University of Rio Grande do Sul University of Sao Paulo